TrialThe Lancet. Haematology2019

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

Graham H Jackson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.